Platelet-Mediated Protection of Cancer Cells From Immune Surveillance - Possible Implications for Cancer Immunotherapy.
NK cells
antitumor immunity
cytotoxicity
immunosuppressive
immunotherapy
metastasis
platelets
tumor microenvironment
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
11
12
2020
accepted:
09
02
2021
entrez:
29
3
2021
pubmed:
30
3
2021
medline:
21
9
2021
Statut:
epublish
Résumé
The growing insights in the complex interactions between metastatic cancer-cells and platelets have revealed that platelet tumor cell interactions in the blood stream are an important factor supporting tumor metastasis. An increased coagulability of platelets facilitates the vascular evasion and establishment of solid tumor metastasis. Furthermore, platelets can support an immunosuppressive tumor microenvironment or shield tumor cells directly from engagement of cytotoxic lymphocytes as e.g., natural killer (NK) cells. Platelets are both in the tumor microenvironment and systemically the quantitatively most important source of TGF-β, which is a key cytokine for immunosuppression in the tumor microenvironment. If similar platelet-tumor interactions are of physiological relevance in hematological malignancies remains less well-studied. This might be important, as T- and NK cell mediated graft vs. leukemia effects (GvL) are well-documented and malignant hematological cells have a high exposure to platelets compared to solid tumors. As NK cell-based immunotherapies gain increasing attention as a therapeutic option for patients suffering from hematological and other malignancies, we review the known interactions between platelets and NK cells in the solid tumor setting and discuss how these could also apply to hematological cancers. We furthermore explore the possible implications for NK cell therapy in patients with solid tumors and patients who depend on frequent platelet transfusions. As platelets have a protective and supportive effect on cancer cells, the impact of platelet transfusion on immunotherapy and the combination of immunotherapy with platelet inhibitors needs to be evaluated.
Identifiants
pubmed: 33777033
doi: 10.3389/fimmu.2021.640578
pmc: PMC7988080
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
640578Informations de copyright
Copyright © 2021 Schmied, Höglund and Meinke.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Thromb Haemost. 2003 Jun;89(6):1098-106
pubmed: 12783124
Science. 2018 Mar 23;359(6382):1361-1365
pubmed: 29567707
ACS Nano. 2020 Aug 25;14(8):9780-9795
pubmed: 32806062
J Immunol Methods. 2004 Nov;294(1-2):15-22
pubmed: 15604012
Dig Surg. 2020;37(6):447-455
pubmed: 32690855
J Immunol. 2014 Jun 15;192(12):5618-24
pubmed: 24795454
Oncoimmunology. 2015 Apr 2;4(9):e1016708
pubmed: 26405590
Blood. 1992 May 1;79(9):2399-403
pubmed: 1349244
J Immunol. 2016 Sep 1;197(5):1663-71
pubmed: 27448586
Oncoimmunology. 2017 Nov 27;7(2):e1364827
pubmed: 29308299
Cancer Res. 2009 Oct 1;69(19):7775-83
pubmed: 19738039
Transl Oncol. 2021 Jan;14(1):100927
pubmed: 33157515
Nat Rev Immunol. 2010 Aug;10(8):554-67
pubmed: 20616810
Nat Rev Clin Oncol. 2021 Feb;18(2):85-100
pubmed: 32934330
Nat Immunol. 2005 Jun;6(6):600-7
pubmed: 15852008
J Immunol. 2013 Jan 15;190(2):821-31
pubmed: 23241893
Clin Exp Metastasis. 2018 Feb;35(1-2):25-35
pubmed: 29322294
J Immunol. 1986 May 15;136(10):3916-20
pubmed: 2871107
J Immunol. 2008 Sep 15;181(6):3784-92
pubmed: 18768831
Int J Cancer. 2015 Jan 1;136(1):234-40
pubmed: 24798403
Blood. 2011 Aug 4;118(5):1190-1
pubmed: 21816838
Neuro Oncol. 2007 Jul;9(3):335-42
pubmed: 17504931
Immunol Today. 1990 Jul;11(7):237-44
pubmed: 2201309
Medicine (Baltimore). 2018 Aug;97(31):e11763
pubmed: 30075601
Blood. 2007 Jul 1;110(1):433-40
pubmed: 17371948
Nano Lett. 2019 Jul 10;19(7):4721-4730
pubmed: 31180684
Sci Rep. 2020 Nov 9;10(1):19296
pubmed: 33168847
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
Clin Cancer Res. 2017 Sep 15;23(18):5611-5621
pubmed: 28611202
Nat Rev Drug Discov. 2020 Mar;19(3):200-218
pubmed: 31907401
Cancer Immunol Immunother. 2016 Apr;65(4):477-84
pubmed: 26810567
J Allergy Clin Immunol. 2013 Sep;132(3):515-525
pubmed: 23993353
Arch Intern Med. 2000 Mar 27;160(6):861-8
pubmed: 10737287
BMC Gastroenterol. 2020 Jan 20;20(1):16
pubmed: 31959103
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4120-5
pubmed: 12646700
PLoS One. 2019 Mar 25;14(3):e0211538
pubmed: 30908480
Br J Haematol. 2014 Aug;166(4):581-91
pubmed: 24797282
Eur J Gynaecol Oncol. 1998;19(1):82-4
pubmed: 9476067
Front Oncol. 2014 Sep 11;4:245
pubmed: 25309871
Cancers (Basel). 2019 Feb 26;11(3):
pubmed: 30813611
Front Immunol. 2019 Jun 04;10:1242
pubmed: 31214193
Blood. 1999 Jul 1;94(1):333-9
pubmed: 10381530
Blood. 2008 Dec 1;112(12):4371-83
pubmed: 19029455
Cell Signal. 2018 Aug;48:45-53
pubmed: 29705335
Immunol Rev. 2001 Jun;181:203-14
pubmed: 11513142
Trends Immunol. 2001 Nov;22(11):633-40
pubmed: 11698225
Am J Pathol. 2004 Feb;164(2):429-39
pubmed: 14742249
Arterioscler Thromb Vasc Biol. 2000 Dec;20(12):2702-8
pubmed: 11116075
Annu Rev Immunol. 2013;31:413-41
pubmed: 23298206
Immunity. 2000 Feb;12(2):171-81
pubmed: 10714683
Semin Oncol. 2014 Jun;41(3):359-69
pubmed: 25023351
Blood. 2005 Jan 1;105(1):178-85
pubmed: 15367435
Sci Immunol. 2017 May 5;2(11):
pubmed: 28763790
Transfus Med Rev. 2020 Oct;34(4):209-220
pubmed: 33051111
Am J Surg. 2005 Mar;189(3):278-82
pubmed: 15792750
Int J Cancer. 2002 Jan 1;97(1):106-14
pubmed: 11774251
Cancers (Basel). 2020 Nov 25;12(12):
pubmed: 33255582
Thromb Haemost. 1990 Dec 28;64(4):501-5
pubmed: 1964750
Adv Immunol. 2014;124:137-70
pubmed: 25175775
J Biol Chem. 1983 Jun 10;258(11):7155-60
pubmed: 6602130
FASEB J. 2007 Aug;21(10):2442-54
pubmed: 17360848
BMJ Open. 2020 Nov 6;10(11):e038172
pubmed: 33158820
J Immunol. 2012 Jul 1;189(1):154-60
pubmed: 22649191
Microbes Infect. 2002 Dec;4(15):1513-21
pubmed: 12505523
Theranostics. 2017 Feb 26;7(5):1062-1071
pubmed: 28435448
Nat Med. 2001 Oct;7(10):1118-22
pubmed: 11590434
Cancer Res. 1999 Mar 15;59(6):1295-300
pubmed: 10096562
Int Immunopharmacol. 2019 Dec;77:105957
pubmed: 31677498
Int J Urol. 2004 Jun;11(6):364-7
pubmed: 15157203
Cancer Res. 2012 Jan 15;72(2):440-8
pubmed: 22127925
J Immunol Methods. 1980;36(3-4):285-91
pubmed: 7430655
Blood Rev. 2019 Mar;34:45-55
pubmed: 30528964